Recce Pharmaceuticals

Activities: Pharmaceutical

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  2. Overcoming CMC challenges in cell and gene therapy: part II Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC...
  3. SNIPR Biome receives funding to progress CRISPR medicine SNIPR001 into clinical trials Phase 1b/2a trial will evaluate SNIPR001 for the prevention of E.coli infections in patients undergoing hematopoietic stem cell transplantation
  4. Kindeva Drug Delivery appoints Denis Johnson as Chief Operating Officer Denis will be responsible for optimising global operations for the company
  5. SeaBeLife awarded over €1.5 million in i-Nov innovation competition Funding for company’s SeaBeEYE project will be used to develop a new therapeutic approach for geographic atrophy, a form of age-related macular degeneration

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

Related Content

Ingredients

Update on progress of broad spectrum antibiotic RECCE 327 towards clinical trials

Recce Pharmaceuticals provides an update on its progress towards the start of human trials of its lead compound RECCE 327, for the treatment of sepsis, including a simple clinical trial design
Recruitment

Pharmaceutical expert joins board of directors

Regulatory

Recce discusses synthetic antibiotic with FDA

The company developing a new class of synthetic antibiotics has been invited to attend a face-to-face meeting with the US Food and Drug Administration
Regulatory

Recce submits additional information to FDA for synthetic antibiotic

Recce Pharmaceuticals, the company developing a new class of synthetic antibiotics, announced it has submitted additional data to the US Food and Drug Administration, including an additional communication request
Regulatory

Recce granted Qualified Infectious Disease Product Designation

Recce, an early stage pharmaceutical company developing a new class of synthetic antibiotics, announced the US Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation for its lead compound RECCE 327
Ingredients

Recce Ltd
Design & Build

Recce constructs automated manufacturing facility to support clinical trials

Recce Limited , a preclinical stage pharmaceutical company engaged in the development of a new class of synthetic antibiotics, has completed construction of a wholly owned production facility in Macquarie Park, Sydney, with expected outputs capable of supporting RECCE 327 through both Phase I and Phase II human trials
Subscribe now